Skip to content
DataLookout
Menu

DEAKTransplantNCT05788276

Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys?

StatusActive, Not Recruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 1 year 1 month later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Jun 2028 to Aug 2029 Show 7 more changesShow less
    • Eligibility criteria expanded, about 12 words
    • Enrollment closed, study ongoing
    • Study completion pushed from Jun 2028 to Sep 2029
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description expanded, about 9 words
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary completion date: Mar 2025 to Jun 2028
    • Eligibility criteria shortened, about 2 words
    • Site details revised
    v3
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2023 to May 2, 2023
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Effect of Dapagliflozin on the GFR slope in renal transplant patients (Main study)
Timeframe: From before randomization to 3 years after transplantation.

Secondary (2)

The effect of Dapagliflozin on renal and metabolic conditions between groups (Main study)
Changes in renal graft fibrosis and proteomic markers with SGLT2 inhibition between groups (Sub-study - the 140 first included patients).

Arms and interventions

Active treatmentActive comparator

165 patients

Control groupPlacebo comparator

165 patients

Drugs: Dapagliflozin 10mg Tab, Placebo

Sites

1 site in 1 country

  • Oslo University HospitalOslo, Oslo, Norway